Maravai LifeSciences (MRVI) Reports In-Line Q3 EPS

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $41.6 million versus the consensus estimate of $49.04 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• FOMC minutes from July 28-29th meeting
• Maravai LifeSciences (MRVI) call put ratio 22 calls to 1 put with a focus on December 5, 7.5 and 10 calls as share price up 25%
• Novavax (NVAX) 11K contracts of August 28 weekly 9 calls trade, share price up 8.8%